Literature DB >> 10225475

Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix.

S C Tyagi1.   

Abstract

Occlusive coronary artery disease is an important factor of cardiovascular morbidity and mortality. The rupture of the thin fibrous cap of the atheroma may be one of the causes of acute coronary syndrome, however, the mechanism of formation of fibrous plaque are poorly understood. Elevation of plasma homocysteine, hyperhomocystinemia, H(e), has emerged as an independent risk factor for hypertension and fibrotic heart disease. The extracellular matrix (ECM) components, particularly fibrillar collagen, are elevated in the atherosclerotic lesions and are the essential integral element in holding the oxidized low density lipoproteins (LDL), homocystine, macrophage and foam cells in milieu, constituting the primary atherosclerotic and secondary restenotic lesions. In vivo and in vitro physiological, morphological, cellular, biochemical and molecular experiments have suggested the role of tissue homocystine in cardiovascular fibrosis and adverse ECM remodeling following H(e). The tissue homocystine induces cardiovascular fibrosis and may lead to heart failure via the redox-receptor pathway. The underlying cause and mechanism of cardiovascular fibrosis associated with arteriosclerosis, atherosclerosis, hypertension and coronary heart disease, involve changes in the levels of tissue redox state.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225475     DOI: 10.3109/10641969909068660

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  20 in total

1.  A functional and histopathological comparison of proximal and distal saphenous vein contractility and morphology.

Authors:  Ilhan Golbasi; Arda Tasatargil; Nazif Hikmet Aksoy; Gulay Sadan; Edibe Karasu; Cengiz Turkay; Omer Bayezid
Journal:  Tex Heart Inst J       Date:  2005

Review 2.  Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective.

Authors:  Casimiro Gerarduzzi; John A Di Battista
Journal:  Inflamm Res       Date:  2016-12-31       Impact factor: 4.575

3.  Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia.

Authors:  Neetu Tyagi; Natia Qipshidze; Utpal Sen; Walter Rodriguez; Alexander Ovechkin; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-08

Review 4.  Homocysteine to hydrogen sulfide or hypertension.

Authors:  Utpal Sen; Paras K Mishra; Neetu Tyagi; Suresh C Tyagi
Journal:  Cell Biochem Biophys       Date:  2010-07       Impact factor: 2.194

5.  Dysbiotic 1-carbon metabolism in cardiac muscle remodeling.

Authors:  Akash K George; Mahavir Singh; S Pushpakumar; Rubens P Homme; Shanna J Hardin; Suresh C Tyagi
Journal:  J Cell Physiol       Date:  2019-09-05       Impact factor: 6.384

6.  Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia.

Authors:  Nino Muradashvili; Reeta Tyagi; Naira Metreveli; Suresh C Tyagi; David Lominadze
Journal:  J Cereb Blood Flow Metab       Date:  2014-05-28       Impact factor: 6.200

Review 7.  Mechanisms of cardiovascular remodeling in hyperhomocysteinemia.

Authors:  Mesia M Steed; Suresh C Tyagi
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 8.  Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling.

Authors:  Thomas P Vacek; Jonathan C Vacek; Suresh C Tyagi
Journal:  Arch Physiol Biochem       Date:  2011-12-19       Impact factor: 4.076

9.  MicroRNAs are involved in homocysteine-induced cardiac remodeling.

Authors:  Paras K Mishra; Neetu Tyagi; Soumi Kundu; Suresh C Tyagi
Journal:  Cell Biochem Biophys       Date:  2009-08-11       Impact factor: 2.194

10.  Plasma and aqueous humour levels of homocysteine in exfoliation syndrome.

Authors:  Tuomo Puustjärvi; Hillevi Blomster; Matti Kontkanen; Kari Punnonen; Markku Teräsvirta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.